Characteristics of triple-negative breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 2, 2011, Pages 183-192

  De Ruijter, Tim C ^a   Veeck, Jürgen ^a   De Hoon, Joep P J ^a   Van Engeland, Manon ^a   Tjan Heijnen, Vivianne C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adjuvant treatment; Basal like breast cancer (BBC); BRCA1; Patient outcome; Triple negative breast cancer (TNBC)

Indexed keywords

4 IODO 3 NITROBENZAMIDE; ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GEMCITABINE; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SURVIVAL; CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG RECEPTOR BINDING; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; GENOTYPE; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE STRANDED DNA BREAK; SOMATIC MUTATION; SURVIVAL TIME; TUMOR REGRESSION;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENOMIC INSTABILITY; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOADJUVANT THERAPY; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78751607122     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0957-x     Document Type: Article

References (87)

1. C Beger LN Pierce M Kruger EG Marcusson JM Robbins P Welcsh PJ Welch K Welte MC King JR Barber F Wong-Staal 2001 Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach Proc Natl Acad Sci USA 98 130 135 1:CAS:528:DC%2BD3MXkslKrsw%3D%3D 10.1073/pnas.98.1.130 11136250 (Pubitemid 32095875)
2. F Bertucci P Finetti N Cervera B Esterni F Hermitte P Viens D Birnbaum 2008 How basal are triple-negative breast cancers? Int J Cancer 123 236 240 1:CAS:528:DC%2BD1cXmtlantbg%3D 10.1002/ijc.23518 18398844 (Pubitemid 351705215)
3. AW Burgess 2008 EGFR family: structure physiology signalling and therapeutic targets Growth Factors 26 263 274 1:CAS:528:DC%2BD1cXhtFamtb%2FM 10.1080/08977190802312844 18800267
4. ML Burness TA Grushko OI Olopade 2010 Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J 16 23 32 1:CAS:528:DC%2BC3cXjvVKkt7Y%3D 10.1097/PPO. 0b013e3181d24fc1 20164687
5. HA Burris III CW Taylor SF Jones KM Koch MJ Versola N Arya RA Fleming DA Smith L Pandite N Spector G Wilding 2009 A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies Clin Cancer Res 15 6702 6708 1:CAS:528:DC%2BD1MXhtlCjsrfJ 10.1158/1078-0432.CCR-09-0369 19825948
6. LA Carey CM Perou CA Livasy LG Dressler D Cowan K Conway G Karaca MA Troester CK Tse S Edmiston SL Deming J Geradts MC Cheang TO Nielsen PG Moorman HS Earp RC Millikan 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492 2502 1:CAS:528:DC%2BD28XlsV2rtLw%3D 10.1001/jama.295.21.2492 16757721 (Pubitemid 43854964)
7. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio DW Ollila CI Sartor ML Graham CM Perou 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 1:CAS:528:DC%2BD2sXkt1enur0%3D 10.1158/1078-0432.CCR-06-1109 17438091 (Pubitemid 46698581)
8. MC Cheang D Voduc C Bajdik S Leung S McKinney SK Chia CM Perou TO Nielsen 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 1368 1376 1:CAS:528:DC%2BD1cXislSrs7o%3D 10.1158/1078-0432.CCR-07-1658 18316557 (Pubitemid 351413917)
9. M Chivukula JM Striebel C Ersahin DJ Dabbs 2008 Evaluation of morphologic features to identify "basal-like phenotype" on core needle biopsies of breast Appl Immunohistochem Mol Morphol 16 411 416 10.1097/PAI. 0b013e3181630e98 18542031
10. LC Collins A Martyniak MJ Kandel ZK Stadler S Masciari A Miron AL Richardson SJ Schnitt JE Garber 2009 Basal Cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers Am J Surg Pathol 33 1093 1097 10.1097/PAS.0b013e3181b7cb7a 19390427
11. B Corkery J Crown M Clynes N O'Donovan 2009 Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer Ann Oncol 20 862 867 1:STN:280:DC%2BD1MzgvVyitw%3D%3D 10.1093/annonc/mdn710 19150933
12. D D'Amours S Desnoyers I D'Silva GG Poirier 1999 Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions Biochem J 342 249 268 10.1042/0264-6021:3420249 10455009 (Pubitemid 29425344)
13. F Dantzer G de La Rubia J Menissier-De Murcia Z Hostomsky G de Murcia V Schreiber 2000 Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1 Biochemistry 39 7559 7569 1:CAS:528: DC%2BD3cXjs1Knsbo%3D 10.1021/bi0003442 10858306 (Pubitemid 30422075)
14. R Dent M Trudeau KI Pritchard WM Hanna HK Kahn CA Sawka LA Lickley E Rawlinson P Sun SA Narod 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 10.1158/1078-0432.CCR- 06-3045 17671126 (Pubitemid 47219710)
15. LK Diaz VL Cryns WF Symmans N Sneige 2007 Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice Adv Anat Pathol 14 419 430 1:CAS:528:DC%2BD2sXhtlCrtb%2FE 10.1097/PAP.0b013e3181594733 18049131 (Pubitemid 350307665)
16. L Dogan C Atalay KB Yilmaz C Ozaslan 2008 Prognosis in hormon receptor negative breast cancer patients according to ERBB2 status Neoplasma 55 544 548 1:STN:280:DC%2BD1cjjtF2muw%3D%3D 18999885
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
18. SL Edwards R Brough CJ Lord R Natrajan R Vatcheva DA Levine J Boyd JS Reis-Filho A Ashworth 2008 Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 1111 1115 1:CAS:528:DC%2BD1cXisFWjtrw%3D 10.1038/nature06548 18264088 (Pubitemid 351317441)
19. EW Elston IO Ellis 1993 Method for grading breast cancer J Clin Pathol 46 189 190 1:STN:280:DyaK3s3htVaitQ%3D%3D 10.1136/jcp.46.2.189-b 8459046
20. M Esteller JM Silva G Dominguez F Bonilla X Matias-Guiu E Lerma E Bussaglia J Prat IC Harkes EA Repasky E Gabrielson M Schutte SB Baylin JG Herman 2000 Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors J Natl Cancer Inst 92 564 569 1:CAS:528:DC%2BD3cXivFWqtr8%3D 10.1093/jnci/92.7.564 10749912
21. PC Fong DS Boss TA Yap A Tutt P Wu M Mergui-Roelvink P Mortimer H Swaisland A Lau MJ O'Connor A Ashworth J Carmichael SB Kaye JH Schellens JS de Bono 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 123 134 1:CAS:528:DC%2BD1MXosVKrtrw%3D 10.1056/NEJMoa0900212 19553641
22. WD Foulkes IM Stefansson PO Chappuis LR Begin JR Goffin N Wong M Trudel LA Akslen 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 95 1482 1485 1:CAS:528:DC%2BD3sXnvVCjtrk%3D 14519755
23. WD Foulkes JS Brunet IM Stefansson O Straume PO Chappuis LR Begin N Hamel JR Goffin N Wong M Trudel L Kapusta P Porter LA Akslen 2004 The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid- microvascular-proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 64 830 835 1:CAS:528:DC%2BD2cXhtFCgtLo%3D 10.1158/0008-5472.CAN-03-2970 14871808 (Pubitemid 38176880)
24. LG Fulford DF Easton JS Reis-Filho A Sofronis CE Gillett SR Lakhani SR Lakhani A Hanby 2006 Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast Histopathology 49 22 34 1:STN:280:DC%2BD28vitFOitQ%3D%3D 10.1111/j.1365-2559.2006.02453.x 16842243 (Pubitemid 43972917)
25. S Ganesan DP Silver RA Greenberg D Avni R Drapkin A Miron SC Mok V Randrianarison S Brodie J Salstrom TP Rasmussen A Klimke C Marrese Y Marahrens CX Deng J Feunteun DM Livingston 2002 BRCA1 supports XIST RNA concentration on the inactive X chromosome Cell 111 393 405 1:CAS:528:DC%2BD38XovVaku7o%3D 10.1016/S0092-8674(02)01052-8 12419249 (Pubitemid 35341392)
26. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global cancer facts & figures 2007. American Cancer Society, Atlanta, GA
27. MD Green PA Francis V Gebski V Harvey C Karapetis A Chan R Snyder A Fong R Basser JF Forbes Australian New Zealand Breast Cancer Trials Group 2009 Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer Ann Oncol 20 1813 1817 1:STN:280:DC%2BD1MjhvVCjsw%3D%3D 10.1093/annonc/mdp202 19553291
28. W Han EM Jung J Cho JW Lee KT Hwang SJ Yang JJ Kang JY Bae YK Jeon IA Park M Nicolau SS Jeffrey DY Noh 2008 DNA copy number alterations and expression of relevant genes in triple-negative breast cancer Genes Chromosomes Cancer 47 490 499 1:CAS:528:DC%2BD1cXlslCksLY%3D 10.1002/gcc.20550 18314908 (Pubitemid 351657184)
29. PM Harari 2004 Epidermal growth factor receptor inhibition strategies in oncology Endocr Relat Cancer 11 689 708 1:CAS:528:DC%2BD2MXhtVarsb8%3D 10.1677/erc.1.00600 15613446 (Pubitemid 40065545)
30. T Hay JR Matthews L Pietzka A Lau A Cranston AO Nygren A Douglas-Jones GC Smith NM Martin M O'Connor AR Clarke 2009 Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin Cancer Res 69 3850 3855 1:CAS:528:DC%2BD1MXltFOksLw%3D 10.1158/0008-5472.CAN-08-2388 19383921
31. I Hedenfalk D Duggan Y Chen M Radmacher M Bittner R Simon P Meltzer B Gusterson M Esteller OP Kallioniemi B Wilfond A Borg J Trent M Raffeld Z Yakhini A Ben-Dor E Dougherty J Kononen L Bubendorf W Fehrle S Pittaluga S Gruvberger N Loman O Johannsson H Olsson G Sauter 2001 Gene-expression profiles in hereditary breast cancer N Engl J Med 344 539 548 1:CAS:528:DC%2BD3MXhsFGks7o%3D 10.1056/NEJM200102223440801 11207349 (Pubitemid 32167867)
32. T Helleday HE Bryant N Schultz 2005 Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy Cell Cycle 4 1176 1178 1:CAS:528:DC%2BD28XktVCgtL8%3D 10.4161/cc.4.9.2031 16123586
33. M Hergueta-Redondo J Palacios A Cano G Moreno-Bueno 2008 "New" molecular taxonomy in breast cancer Clin Transl Oncol 10 777 785 1:CAS:528:DC%2BD1MXksF2isw%3D%3D 10.1007/s12094-008-0290-x 19068448
34. KA Hoadley VJ Weigman C Fan LR Sawyer X He MA Troester CI Sartor T Rieger-House PS Bernard LA Carey CM Perou 2007 EGFR associated expression profiles vary with breast tumor subtype BMC Genomics 8 258 10.1186/1471-2164-8- 258 17663798 (Pubitemid 47559211)
35. X Hu HM Stern L Ge C O'Brien L Haydu CD Honchell PM Haverty BA Peters TD Wu LC Amler J Chant D Stokoe MR Lackner G Cavet 2009 Genetic alterations and oncogenic pathways associated with breast cancer subtypes Mol Cancer Res 7 511 522 1:CAS:528:DC%2BD1MXks1antb0%3D 10.1158/1541-7786.MCR-08-0107 19372580
36. J Hugh J Hanson MC Cheang TO Nielsen CM Perou C Dumontet J Reed M Krajewska I Treilleux M Rupin E Magherini J Mackey M Martin C Vogel 2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial J Clin Oncol 27 1168 1176 1:CAS:528:DC%2BD1MXktFKhs7Y%3D 10.1200/JCO.2008.18.1024 19204205
37. HK Johannsdottir G Jonsson G Johannesdottir BA Agnarsson H Eerola A Arason P Heikkila V Egilsson H Olsson OT Johannsson H Nevanlinna A Borg RB Barkardottir 2006 Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors Int J Cancer 119 1052 1060 1:CAS:528:DC%2BD28Xns1Cms7Y%3D 10.1002/ijc.21934 16570289 (Pubitemid 44116912)
38. HG Kaplan JA Malmgren 2008 Impact of triple negative phenotype on breast cancer prognosis Breast J 14 456 463 10.1111/j.1524-4741.2008.00622.x 18657139
39. S Kyle HD Thomas J Mitchell NJ Curtin 2008 Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer Br J Radiol 81 Spec No 1 6 11 10.1259/bjr/99111297
40. SR Lakhani JS Reis-Filho L Fulford F Penault-Llorca M van der Vijver S Parry T Bishop J Benitez C Rivas YJ Bignon J Chang-Claude U Hamann CJ Cornelisse P Devilee MW Beckmann C Nestle-Krämling PA Daly N Haites J Varley F Lalloo G Evans C Maugard H Meijers-Heijboer JG Klijn E Olah BA Gusterson S Pilotti P Radice S Scherneck H Sobol J Jacquemier T Wagner J Peto MR Stratton L McGuffog DF Easton Breast Cancer Linkage Consortium 2005 Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype Clin Cancer Res 11 5175 5180 1:CAS:528:DC%2BD2MXmt12qtbk%3D 10.1158/1078-0432.CCR-04- 2424 16033833 (Pubitemid 41003703)
41. C Liedtke C Mazouni KR Hess F Andre A Tordai JA Mejia WF Symmans AM Gonzalez-Angulo B Hennessy M Green M Cristofanilli GN Hortobagyi L Pusztai 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 10.1200/JCO.2007.14.4147 18250347
42. S Mason M Piper RM Gronostajski LJ Richards 2009 Nuclear factor one transcription factors in CNS development Mol Neurobiol 39 10 23 1:CAS:528:DC%2BD1MXht1Grtb8%3D 10.1007/s12035-008-8048-6 19058033
43. E Matros ZC Wang G Lodeiro A Miron JD Iglehart AL Richardson 2005 BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles Breast Cancer Res Treat 91 179 186 1:CAS:528:DC%2BD2MXjvVWjsro%3D 10.1007/s10549-004-7603-8 15868446 (Pubitemid 40684930)
44. A Meche AM Cimpean M Raica 2009 Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer Rom J Morphol Embryol 50 217 221 19434314
45. H Mersin E Yildirim U Berberoglu K Gulben 2008 The prognostic importance of triple negative breast carcinoma Breast 17 341 346 10.1016/j.breast.2007.11. 031 18450442
46. SR Morris LA Carey 2007 Gene Expression profiling in Breast Cancer Curr Opin Oncol 19 547 551 1:CAS:528:DC%2BD2sXhtFSnu7zI 10.1097/CCO.0b013e3282f0ada3 17906450 (Pubitemid 47508859)
47. GJ Morris S Naidu AK Topham F Guiles Y Xu P McCue GF Schwartz PK Park AL Rosenberg K Brill EP Mitchell 2007 Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database Cancer 110 876 884 10.1002/cncr.22836 17620276 (Pubitemid 47257667)
48. H Nalwoga JB Arnes H Wabinga LA Akslen 2008 Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women APMIS 116 515 525 1:CAS:528:DC%2BD1cXpslKitrw%3D 10.1111/j.1600-0463.2008. 01024.x 18754326
49. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu T Hernandez-Boussard C Livasy D Cowan L Dressler LA Akslen J Ragaz AM Gown CB Gilks M van de Rijn CM Perou 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 1:CAS:528:DC%2BD2cXmvFSlt7k%3D 10.1158/1078-0432.CCR-04-0220 15328174 (Pubitemid 39100473)
50. R Nishimura N Arima 2008 Is triple negative a prognostic factor in breast cancer? Breast Cancer 15 303 308 10.1007/s12282-008-0042-3 18369692
51. S Nofech-Mozes M Trudeau HK Kahn R Dent E Rawlinson P Sun SA Narod WM Hanna 2009 Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers Breast Cancer Res Treat 118 131 137 10.1007/s10549-008-0295-8 19189211
52. H Nogi T Kobayashi M Suzuki I Tabei K Kawase Y Toriumi H Fukushima K Uchida 2009 EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer Oncol Rep 21 413 417 1:CAS:528: DC%2BD1MXit1Grtro%3D 19148516
53. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C (2008) Efficacy of BSI-201. A poly (ADP-ribose) polymerase (PARP1) inhibitor, in combination with gemcitamine/carboplatin in patients with metastatic triple negative breast cancer: results of a randomized phase II trial. J Clin Oncol 26: May 20 suppl; abstr 1015
54. C Oliveras-Ferraros A Vazquez-Martin E Lopez-Bonet B Martin-Castillo S Del Barco J Brunet JA Menendez 2008 Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer Int J Oncol 33 1165 1176 1:CAS:528:DC%2BD1cXhsFams7jN 19020749
55. Page DL (2003) Special types of invasive breast cancer, with clinical implications. Am J Surg Pathol 27:832-825
56. RR Parikh D Housman Q Yang D Toppmeyer LD Wilson BG Haffty 2008 Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer Int J Radiat Oncol Biol Phys 72 1056 1063 10.1016/j.ijrobp.2008.02.066 18676094
57. A Perren LP Weng AH Boag U Ziebold K Thakore PL Dahia P Komminoth JA Lees LM Mulligan GL Mutter C Eng 1999 Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast Am J Pathol 155 1253 1260 1:CAS:528:DyaK1MXntFWmt7g%3D 10514407
58. T Pienkowski CC Zielinski 2010 Trastuzumab treatment in patients with breast cancer and metastatic CNS disease Ann Oncol 21 917 924 1:STN:280:DC%2BC3c3ptFOmtA%3D%3D 10.1093/annonc/mdp353 19717536
59. EA Rakha ME El-Sayed AR Green AH Lee JF Robertson IO Ellis 2007 Prognostic markers in triple-negative breast cancer Cancer 109 25 32 1:CAS:528:DC%2BD2sXhtVKrtLY%3D 10.1002/cncr.22381 17146782 (Pubitemid 46120191)
60. EA Rakha SE Elsheikh MA Aleskandarany HO Habashi AR Green DG Powe ME El-Sayed A Benhasouna JS Brunet LA Akslen AJ Evans R Blamey JS Reis-Filho WD Foulkes IO Ellis 2009 Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes Clin Cancer Res 15 2302 2310 1:CAS:528: DC%2BD1MXjvVWltbs%3D 10.1158/1078-0432.CCR-08-2132 19318481
61. J Rhee SW Han DY Oh JH Kim SA Im W Han IA Park DY Noh YJ Bang TY Kim 2008 The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer BMC Cancer 8 307 10.1186/1471-2407-8-307 18947390
62. AL Richardson ZC Wang A De Nicolo X Lu M Brown A Miron X Liao JD Iglehart DM Livingston S Ganesan 2006 X chromosomal abnormalities in basal-like human breast cancer Cancer Cell 9 121 132 1:CAS:528:DC%2BD28XhvFynsrg%3D 10.1016/j.ccr.2006.01.013 16473279 (Pubitemid 43202662)
63. SM Rodriguez-Pinilla D Sarrio E Honrado G Moreno-Bueno D Hardisson F Calero J Benítez J Palacios 2007 Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas J Clin Pathol 60 1006 1012 10.1136/jcp.2006.042143 17105822 (Pubitemid 47441933)
64. A Rody T Karn C Solbach R Gaetje M Munnes S Kissler E Ruckhäberle GV Minckwitz S Loibl U Holtrich M Kaufmann 2007 The erbB2 + cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial Breast 16 235 240 1:STN:280:DC%2BD2szis12gsw%3D%3D 10.1016/j.breast.2007.02.006 17449250 (Pubitemid 46796861)
65. S Rottenberg JE Jaspers A Kersbergen E van der Burg AO Nygren SA Zander PW Derksen M de Bruin J Zevenhoven A Lau R Boulter A Cranston MJ O'Connor NM Martin P Borst J Jonkers 2008 High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc Natl Acad Sci USA 105 17079 17084 1:CAS:528:DC%2BD1cXhtlKlsr7F 10.1073/pnas.0806092105 18971340
66. R Rouzier CM Perou WF Symmans N Ibrahim M Cristofanilli K Anderson KR Hess J Stec M Ayers P Wagner P Morandi C Fan I Rabiul JS Ross GN Hortobagyi L Pusztai 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 1:CAS:528: DC%2BD2MXos1Cjs7k%3D 10.1158/1078-0432.CCR-04-2421 16115903 (Pubitemid 41170290)
67. LH Saal K Holm M Maurer L Memeo T Su X Wang JS Yu PO Malmström M Mansukhani J Enoksson H Hibshoosh A Borg R Parsons 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma Cancer Res 65 2554 2559 1:CAS:528:DC%2BD2MXjtVeqsrc%3D 10.1158/0008-5472-CAN-04-3913 15805248 (Pubitemid 40490050)
68. LH Saal SK Gruvberger-Saal C Persson K Lovgren M Jumppanen J Staaf G Jönsson MM Pires M Maurer K Holm S Koujak S Subramaniyam J Vallon-Christersson H Olsson T Su L Memeo T Ludwig SP Ethier M Krogh M Szabolcs VV Murty J Isola H Hibshoosh R Parsons A Borg 2008 Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair Nat Genet 40 102 107 1:CAS:528:DC%2BD1cXhtVyqsA%3D%3D 10.1038/ng.2007.39 18066063
69. S Samphao JM Eremin M El-Sheemy O Eremin 2009 Treatment of established breast cancer in post-menopausal women: role of aromatase inhibitors Surgeon 7 42 55 1:STN:280:DC%2BD1M7ms1OmtQ%3D%3D 10.1016/S1479-666X(09)80066-8 19241985
70. B Sirohi M Arnedos S Popat S Ashley A Nerurkar G Walsh S Johnston IE Smith 2008 Platinum-based chemotherapy in triple-negative breast cancer Ann Oncol 19 1847 1852 1:STN:280:DC%2BD1cnosVCqsQ%3D%3D 10.1093/annonc/mdn395 18567607
71. Sobin LH, Gospodarowicz MK, Wittekind CH (2009) UICC: TNM classification of malignant tumors. Wiley-Blackwell, Oxford
72. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist JC Matese PO Brown D Botstein P Eystein Lønning AL Børresen-Dale 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 1:CAS:528:DC%2BD3MXntVGmsbo%3D 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
73. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel S Deng H Johnsen R Pesich S Geisler J Demeter CM Perou PE Lønning PO Brown AL Børresen-Dale D Botstein 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423 1:CAS:528:DC%2BD3sXlsFGntLk%3D 10.1073/pnas.0932692100 12829800 (Pubitemid 36842560)
74. AL Stratford G Habibi A Astanehe H Jiang K Hu E Park A Shadeo TP Buys W Lam T Pugh M Marra TO Nielsen U Klinge PR Mertens S Aparicio SE Dunn 2007 Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy Breast Cancer Res 9 R61 10.1186/bcr1767 17875215 (Pubitemid 350187482)
75. AR Tan SM Swain 2008 Therapeutic strategies for triple-negative breast cancer Cancer J 14 343 351 1:CAS:528:DC%2BD1MXhtVWrtLY%3D 10.1097/PPO. 0b013e31818d839b 19060597
76. Tavassoli FA, Devilee P (2003) World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon
77. XS Tian MH Cong WH Zhou J Zhu YZ Chen Q Liu 2008 Clinicopathologic and prognostic characteristics of triple-negative breast cancer Onkologie 31 610 614 1:CAS:528:DC%2BD1cXhsFCrsLvJ 10.1159/000162288 19145094
78. M Tischkowitz JS Brunet LR Begin DG Huntsman MC Cheang LA Akslen TO Nielsen WD Foulkes 2007 Use of immunohistochemical markers can refine prognosis in triple negative breast cancer BMC Cancer 7 134 10.1186/1471-2407-7-134 17650314 (Pubitemid 47272190)
79. NC Turner JS Reis-Filho AM Russell RJ Springall K Ryder D Steele K Savage CE Gillett FC Schmitt A Ashworth AN Tutt 2007 BRCA1 dysfunction in sporadic basal-like breast cancer Oncogene 26 2126 2132 1:CAS:528:DC%2BD2sXjsFSiu7c%3D 10.1038/sj.onc.1210014 17016441 (Pubitemid 46514749)
80. A Tutt A Ashworth 2002 The relationship between the roles of BRCA genes in DNA repair and cancer predisposition Trends Mol Med 8 571 576 1:CAS:528:DC%2BD38XptFGmu7o%3D 10.1016/S1471-4914(02)02434-6 12470990 (Pubitemid 35408215)
81. A Tutt M Robson JE Garber SM Domchek MW Audeh JN Weitzel M Friedlander B Arun N Loman RK Schmutzler A Wardley G Mitchell H Earl M Wickens J Carmichael 2010 Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 235 244 1:CAS:528:DC%2BC3cXpt1KktLc%3D 10.1016/S0140-6736(10)60892-6 20609467
82. Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M (2010) BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)-Ribose Polymerase Inhibitors. J Clin Oncol doi: 10.1200/JCO.2010.30.1010
83. G Viale N Rotmensz P Maisonneuve L Bottiglieri E Montagna A Luini P Veronesi M Intra R Torrisi A Cardillo E Campagnoli A Goldhirsch M Colleoni 2009 Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity Breast Cancer Res Treat 116 317 328 1:CAS:528:DC%2BD1MXntF2ntr8%3D 10.1007/s10549-008-0206-z 18839307
84. G von Minckwitz W Jonat P Fasching A du Bois U Kleeberg HJ Luck HJ Lück E Kettner J Hilfrich W Eiermann J Torode A Schneeweiss 2005 A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer Breast Cancer Res Treat 89 165 172 1:CAS:528: DC%2BD2MXhtVamsro%3D 10.1007/s10549-004-1720-2 (Pubitemid 40249050)
85. G von Minckwitz B Müller S Loibl JU Blohmer A duBois J Huober R Kandolf J Budczies C Denkert 2010 PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy Eur J Cancer (Supplements) 8 188 10.1016/S1359-6349(10)70464-X
86. S Wang H Yang F Tong J Zhang D Yang H Liu Y Cao P Liu P Zhou L Cheng M Liu J Guo 2009 Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer Gan To Kagaku Ryoho 36 255 258 19223741
87. B Weigelt HM Horlings B Kreike MM Hayes M Hauptmann LF Wessels D de Jong MJ Van de Vijver LJ Van't Veer JL Peterse 2008 Refinement of breast cancer classification by molecular characterization of histological special types J Pathol 216 141 150 1:CAS:528:DC%2BD1cXht1Gqs7fK 10.1002/path.2407 18720457